What was a key requirement for EBLIS patients?

What was a key requirement for EBLIS patients?

• A. Stage IV disease
• B. Low risk for relapse
• C. High risk for relapse
• D. BRCA mutation presence

Answer: (C)

Clinical trials in cancer often require enrolling patients who are at higher risk of relapse so the treatment effect on relapse can be detected. When relapse risk is high, there are more events to measure relapse-free survival, making it easier to see whether the intervention actually helps prevent recurrence. This is why a high risk for relapse is the best fit for the key requirement. Stage IV disease is metastatic and typically represents a different study population focused on overall survival or systemic disease control, not specifically on relapse prevention in a higher-risk but non-metastatic group. A low risk for relapse would yield too few events to reliably assess an effect. BRCA mutation presence could define a genetic subgroup, but it isn’t the relapse-risk criterion itself unless the trial is specifically testing a BRCA-defined cohort; the question points to relapse risk as the deciding feature.

Clinical trials in cancer often require enrolling patients who are at higher risk of relapse so the treatment effect on relapse can be detected. When relapse risk is high, there are more events to measure relapse-free survival, making it easier to see whether the intervention actually helps prevent recurrence. This is why a high risk for relapse is the best fit for the key requirement.

Stage IV disease is metastatic and typically represents a different study population focused on overall survival or systemic disease control, not specifically on relapse prevention in a higher-risk but non-metastatic group. A low risk for relapse would yield too few events to reliably assess an effect. BRCA mutation presence could define a genetic subgroup, but it isn’t the relapse-risk criterion itself unless the trial is specifically testing a BRCA-defined cohort; the question points to relapse risk as the deciding feature.